Top 35 Biotech Startups to Watch in Europe
Europe’s next generation of biotech companies isn’t only coming from the usual hubs. We pulled...
Top 10 Biotech Exits in Europe Since 2023
Europe’s biotech M&A market has been on a tear. Since 2023, acquirers from MSD to...
Consumer Biotech’s Next Wave: Muscle, Sex, and Psychedelics
GLP-1 drugs have shown the world that blockbuster medicines don’t have to treat disease in...
Top 50 Investors in Biotech in 2026: Europe’s Most Active Life Sciences Funds
Who is writing the cheques that fund Europe’s next generation of medicines? Based on fund...
ASCO 2026: ADC and In Vivo CAR-T Trends in Oncology
What are the biggest trends shaping oncology investment and drug development in 2026? We sat...
How Next-Generation Sequencing is Changing Biopharma Manufacturing
In the strictly regulated world of biopharmaceutical manufacturing, innovation faces a massive hurdle: the industry...
The $6 Billion Excel Illusion: Why Biotech Pipeline Forecasting is Broken (And How to Fix It)
If you sit in a Big Pharma boardroom during a pipeline review, you will inevitably...
The Biotech Equity Gap: Why Curie.Bio is Re-Writing the Founder Playbook
In the high-stakes world of drug discovery, a “brilliant idea” is often described as being...
How Europe could have more Biotech Champions like Argenx
For decades, the narrative of European biotech has been one of “innovation flight”: brilliant science...
Why Antimicrobial Resistance Is Bigger Than Cancer
We’ve been hearing about the Antimicrobial Resistance (AMR) crisis for over a decade. Yet, according...
